Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tonix Pharmaceuticals Holding (TNXP) Invested Capital: 2023-2025

Historic Invested Capital for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $231.1 million.

  • Tonix Pharmaceuticals Holding's Invested Capital rose 186.26% to $231.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.1 million, marking a year-over-year increase of 186.26%. This contributed to the annual value of $148.2 million for FY2024, which is 27.19% up from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Invested Capital of $231.1 million as of Q3 2025, which was up 37.58% from $168.0 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Invested Capital high stood at $231.1 million for Q3 2025, and its period low was $49.3 million during Q2 2024.
  • Moreover, its 3-year median value for Invested Capital was $140.5 million (2023), whereas its average is $137.9 million.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Invested Capital crashed by 64.87% in 2024, and later spiked by 240.48% in 2025.
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Invested Capital stood at $116.5 million in 2023, then rose by 27.19% to $148.2 million in 2024, then soared by 186.26% to $231.1 million in 2025.
  • Its Invested Capital stands at $231.1 million for Q3 2025, versus $168.0 million for Q2 2025 and $180.4 million for Q1 2025.